New publication in MABS 2024

Structural analysis of light chain-driven bispecific antibodies targeting CD47 andPD-L1

Pauline Malinge^a*, Xavier Chauchet^a*, Jérémie Bourguignon^a, Nicolas Bosson^a, Sébastien Calloud^a, Tereza Bautzova^a,Marie Borlet^a, Mette Laursen^b, Vinardas Kelpsas^b, Nadia Rose^b, Franck Gueneau^a, Ulla Ravn^a, Giovanni Magistrelli^a,and Nicolas Fischer^a

Light Chain Bioscience is thrilled to share in our recent article published in mAbs, some structural insights on how antibody light chains can drive antigen binding.

Read: Full article

In contrast to natural antibodies that rely mainly on the heavy chain to establish contacts with their cognate antigen, we have developed a bispecific antibody format, called the kappa-lambda body (κλ body), bearing a common heavy chain and two different light chains that drive antigen binding and specificity of each arm of the bispecific antibody.

The structures can be found here :

https://www.rcsb.org/structure/8RP8

https://www.rcsb.org/structure/8RPB

Importantly, κλ bodies retain truly native human sequences and structure, maximizing their therapeutic potential. Currently three bispecific κλ bodies are undergoing evaluation in Phase I clinical trials.

Light Chains can do it!

Published: June 7th,  2024│volume 16, Article 2362432

Back to News